superior risankizumab efficacy vs. apremilast in systemic-eligible moderate psoriasis.
Published 1 year ago • 207 plays • Length 6:12
Download video MP4
Download video MP3
Similar videos
-
6:01
efficacy and safety of secukinumab in psoriasis over 5 years, r. langley et al.
-
2:54
long-term efficacy and safety of tildrakizumab, k. reich et al
-
2:02
efficacy and safety of mirikizumab in psoriasis: oasis-1, a. blauvelt et al
-
3:55
secukinumab in moderate-to-severe plaque psoriasis, k. reich et al
-
2:53
phase ii study of izokibep for moderate-to-severe plaque psoriasis, s. gerdes et al
-
3:10
secukinumab individualized dosing in chronic plaque psoriasis, k. reich et al
-
15:24
lecture-120: introduction to apremilast in psoriasis
-
7:11
shiseido benefiance wrinkle smoothing eye cream | arantzazu bellido | @almaverso. @shiseido
-
5:02
safety and efficacy of amlitelimab in ad: a phase iia rct, s. weidinger et al.
-
16:59
pde4 inhibitors apremilast
-
2:34
omalizumab in bp: french national multicentre retrospective study, r. chebani et al.
-
2:39
biosimilars for psoriasis, a. blauvelt et al
-
1:57
uptake of biosimilars for psoriasis, d.b. phan, et al
-
9:49
fda approves label update to include additional data for otezla ® (apremilast)
-
2:28
safety, efficacy and drug survival of biologics and biosimilars, a. egeberg et al
-
1:13
compass analysis: guselkumab vs. ustekinumab for plaque psoriasis, j. diels et al
-
13:22
identification of novel therapeutic targets in psoriasis skin: an isoform approach- by susana poveda
-
5:46
plaque psoriasis: ultimma and other trials
-
6:38
results of phase iii trial of lebrikizumab in moderate-to-severe ad at 52 weeks, a. blauvelt et al.
-
4:00
umbralisib ublituximab shows superior outcomes to standard of care chemoimmunotherapy in cll
-
3:35
fatigue in psoriasis, i.m. skoie et al
Clip.africa.com - Privacy-policy